Combating diseases with small molecule compounds

Slides:



Advertisements
Similar presentations
The Drug Discovery Process
Advertisements

Chapter 19 Lecture Concepts of Genetics Tenth Edition Cancer and Regulation of the Cell Cycle.
Small Molecules for Better Sight March 2013 Company Presentation March 2013 Company Presentation.
Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia Glenn A. Reinhart, Ph.D. Senior Group Leader Integrative.
Turmeric – Currying Favour with Cancer Experts A Presentation by Greg Thornton.
Tissue Repair Dr. Raid Jastania. What is Repair? When does regeneration occur? When does fibrosis occur? What are the consequences of fibrosis?
Figure S1. ID#1 Lipid Metabolism, Small Molecule Biochemistry, Drug Metabolism.
Cyclin dependent kinases as therapeutic agents in Rheumatoid Arthritis
Viruses and Cancer BTY328: Virology
Apoptosis-related Diseases  Insufficient apoptosis  Excessive apoptosis  Coexistence of insufficient and excessive apoptosis.
Regulation of the Cell Cycle. Molecular Control System Normal growth, development and maintenance depend on the timing and rate of mitosis Cell-cycle.
1.Nowell, PC. The clonal evolution of tumor cell populations. Science (1976) 194: Cavenee, WK & White, RL. The genetic basis of cancer. Scientific.
Partnering with Federal Labs: A Panel Discussion FLC Mid-Atlantic Region Annual Meeting October 24, 2007.
Kyoto University, Japan
Garlic & Health:Health part - general aim Main Goal:- Interactive improvement of garlic quality Elucidation of mechanism Analysis of active of action compoundsImproved.
Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.
BIOL 445 – CANCER BIOLOGY PRESENTATION
RA190 Small Molecule Proteasome Inhibitor for Cancer Therapy.
Samudrala group - overall research areas CASP6 prediction for T Å C α RMSD for all 70 residues CASP6 prediction for T Å C α RMSD for all.
○ Area Yonsei Biomedical Science and Technology Initiative (YBSTI)
Phospholipids Analogs as a New Anti-Inflammatory Anti- Atherosclerosis Therapy Dror Harats The Institute of Lipids and Atherosclerosis Research, Sheba.
Wound Healing Dr. Raid Jastania.
AH Biology: Unit 1 Control of the Cell Cycle. The cell cycle: summary G1G1 G2G2 S Interphase M Cytokinesis Mitosis.
Cancer Accelerated Biology. Learning Objectives The different methods of diagnosing cancer. The difference between a malignant tumor and a benign tumor.
A PRESENTATION ON “In Ovo Mefloquine and 4-Aminopyridine administration inhibits chorioallantoic membrane (CAM) angiogenesis in chicken embryos through.
NAJRAN UNIVERSITY College of Medicine NAJRAN UNIVERSITY College of Medicine Microbiology &Immunology Course Lecture No. 17 Microbiology &Immunology Course.
ANTI-VEGF Recent Advances in DR. VEGF- Vascular Endothelial Growth factor is an important growth factor for angiogenesis and is necessary for normal angiogenesis.
Targeted Drug Therapeutics An overview of our technologies and their potential 505(b)(2) applications Sino-American Regulatory Consulting Alliance Yongtian.
Molecular Biomarkers & Targets an overview Michael Messenger NIHR Diagnostic Evidence Co-Operative & Leeds Cancer Research UK Centre.
A model collaboration using the Pool Susanne Hollinger, Ph.D., J.D. Chief Intellectual Property Officer Emory University.
26th April 2016, BioTrinity - London
A novel therapy and companion biomarker for Alzheimer’s disease.
Passion is our driver, strategy is our compass May 6, 2016.
Page 1 What is TNFWhat is TNF? --Creative BioMart.
A Clinical Stage Drug Company Developing Polymolecular Therapeutics For The Oncology, Neurology And Orthopedic Markets Dr. Brent Reynolds, CEO
A Clinical Stage Drug Company Developing Polymolecular Therapeutics For The Oncology, Neurology And Orthopedic Markets Dr. Brent Reynolds, CEO
M1 – Immunology CYTOKINES AND CHEMOKINES March 26, 2009 Ronald B
GENETIC BIOMARKERS.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Can Drug Discovery Research be Done At An Undergraduate Institution?
Developing chemically modified, non-anticoagulant heparin derivatives as galectin-3-targeted novel anti-cancer/anti-metastasis drugs Professor Lu-Gang.
A REVIEW AND UPDATE ON THE ANTI-ANGIOGENIC AGENT, ABT-510
Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small.
An Introduction to Medicinal Chemistry 3/e
Cancer as a genetic disease
Darts Sciences Darts Target Identification.
Structural Bioinformatics in Drug Discovery
Inducing Angiogenesis
Figure 1 Cellular processes involved in cancer development
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Figure 1 A schematic representation of the HER2 signalling pathway
Therapeutic targeting of the tumor microenvironment
Hallmarks of Cancer.
Nat. Rev. Urol. doi: /nrurol
Advertisement for the post of JRF in DST funded project
Nat. Rev. Rheumatol. doi: /nrrheum
Advancing the Treatment of IBD With Biologics
Immunohistochemical (IHC) staining for CD117 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis.
Immunological Technique
Biological Therapies for Inflammatory Bowel Diseases
Figure 2 Emerging hallmarks of T cells in rheumatoid arthritis
Figure 4 Senotherapeutic targeting strategies
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Schematic overview of different immune processes in blood during the development of RA. Upper left: CD56dim NK cells are capable of killing autoimmune.
Schematic illustration of the concepts in the pathogenesis of rheumatoid arthritis associated-interstitial lung disease (RA-ILD). Schematic illustration.
Low-dose glucocorticoid chronotherapy in rheumatoid arthritis (RA) include the night-time-release prednisone, a timing drug release formulation with administration.
The effects of prostanoids on vasculature and blood cells; a variety of vascular cells, platelets and leukocytes have been identified as targets for the.
Prof Matt Smalley, Director
Presentation transcript:

Combating diseases with small molecule compounds 11.04.2017 Combating diseases with small molecule compounds C3BIO GmbH Confidential 11.04.2017

Company concept: rational drug design 11.04.2017 Company concept: rational drug design Patents and exclusive world licenses on families of compounds (purines and pyrazolopyrimidines) Extensive network of cooperation partners Progress made in 3 indication areas: Rheumatoid arthritis, restenosis and cancer Confidential 11.04.2017

11.04.2017 Pyrazolopyrimidines Roscovitine Confidential 11.04.2017

Cancer Recognized hallmarks of cancers Uncontrolled proliferation 11.04.2017 Cancer Recognized hallmarks of cancers Uncontrolled proliferation Evasion of apoptosis Sustained angiogenesis Genomic instability Common target: cyclin-dependent kinases (CDKs) AR – aminoroscovitines (libor havl) BA - hydroxylhalogenroscovitines (maros zatlokal) Confidential 11.04.2017

Cancer Identified compounds have increased: 11.04.2017 Cancer Identified compounds have increased: Activity in biochemical and cellular assays Potency in vivo Metabolic stability Tumour cell migration as well as endothelial migration are specifically being investigated to prevent cancer metastasis-a number of compounds show promising results AR – aminoroscovitines (libor havl) BA - hydroxylhalogenroscovitines (maros zatlokal) Confidential 11.04.2017

11.04.2017 Restenosis Focus is on identification of new drug candidates interfering with vascular smooth muscle cells (VSMC) proliferation Identified compounds may be useful for anti-restenotic therapy-some of the work is published Confidential 11.04.2017

11.04.2017 Rheumatoid Arthritis Concentrate on the 30-40% non-responding RA patients New targets-neutrophils and synovial fibroblasts Patients at early stage of disease progression Confidential 11.04.2017

Rheumatoid Arthritis: LGR1407 induces neutrophil apoptosis 11.04.2017 Rheumatoid Arthritis: LGR1407 induces neutrophil apoptosis Confidential 11.04.2017

11.04.2017 Rheumatoid Arthritis: LGR1407 inhibits TNF-induced secretion of IL-8 in neutrophils Confidential 11.04.2017

11.04.2017 Rheumatoid Arthritis: LGR1407 inhibits proliferation of synovial fibroblasts from RA patients Confidential 11.04.2017

Molecular target had been identified Compounds are orally available 11.04.2017 Rheumatoid Arthritis Molecular target had been identified Compounds are orally available Toxicology and pharmacokinetic studies indicate a useful therapeutic window in vivo studies successfully carried out 11.04.2017

Combating diseases with small molecule compounds 11.04.2017 Combating diseases with small molecule compounds For more information contact Dr. Paul Pechan, CEO Email:ppechan@compuserve.com Tel: 49 89 67847951 Confidential 11.04.2017

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.